Levetiracetam IV

Phase 3Small molecule

AAssistance Publique - Hôpitaux de Paris

Levetiracetam IV is one of 84 small molecule programs targeting Encephalopathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EncephalopathyActive, not recruiting

SeizureActive, not recruiting

EncephalopathyPhase 3

Active, not recruiting

SeizurePreclinical

Active, not recruiting

Competition

Competitive Landscape

135 competitors in Encephalopathy

#DrugCompanyPhaseTrials

Xifaxan

SSalix

Phase 3

21 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

1 3

Alinia

RRomark Laboratories L.C.

Phase 3

4 4

PROCRIT

WWim Janssens

Phase 3

3 5

Cafcit

KKaken Pharmaceutical

Phase 3

1 6

Aranesp

Amgen

Phase 2

3 7

Fludara

Sanofi

Phase 2

1 8

Yescarta

Gilead

Phase 2

1 9

VSL#3

CCD Pharma India Pvt. Ltd.

Phase 3

2 10

Erythropoietin-Beta

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Not yet recruiting

Encephalopathy

NCT06851078

Clinical

Trials by Indication[1]

Encephalopathy1 trial

Evaluation of Early Administration of Levetiracetam in the Prevention and Treatment Encephalopathy in Septic Shock: Randomized, Double-blind, Placebo-controlled Trial

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06851078·280 enrolled

Seizure1 trial

Levetiracetam Versus Phenobarbital in Benzodiazepines Unresponsive Paediatric Prolonged Seizures

Recruiting·MMinistry of Health and Sports, Myanmar·N/A·NCT07098728·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Levetiracetam IV. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Levetiracetam IV compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Levetiracetam IV. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAssistance Publique - Hôpitaux de Paris

Levetiracetam IV

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Encephalopathy1 trial

Seizure1 trial

References

Drug Info

Quick Facts

Related News